Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806341 | 0.93 | HSD11B1 (0.60) | HSD11B1SPRPRMT5WDR77USP30 | |
| SCHEMBL31228434 | 0.86 | HSD11B1 (0.49) | HSD11B1SPRPRMT5WDR77USP30 | |
| SCHEMBL1740411 | 0.86 | HSD11B1 (0.49) | HSD11B1SPRPRMT5WDR77USP30 | |
| SCHEMBL4074303 | 0.83 | HSD11B1 (0.53) | HSD11B1SPRUSP30KDM5ANAMPT | |
| SCHEMBL13490506 | 0.81 | JAK2 (0.55) | PRMT5WDR77USP30GRM5 | |
| SCHEMBL13490412 | 0.81 | KDM5A (0.54) | HSD11B1USP30KDM5AMAP3K12MAP4K4 | |
| SCHEMBL4003240 | 0.80 | GPR119 (0.55) | HSD11B1PRMT5WDR77USP30KDM5A | |
| SCHEMBL17888462 | 0.80 | PROKR1 (0.58) | KDM5AMAP3K12NAMPTPROKR1 | |
| SCHEMBL30919809 | 0.80 | GPR119 (0.55) | HSD11B1PRMT5WDR77USP30KDM5A | |
| SCHEMBL6351706 | 0.80 | DRD4 (0.47) | HSD11B1SPRPRMT5WDR77USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | HSD11B1 136/4885SPR 773/4885PRMT5 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.